For oral squamous cell carcinoma (OSCC), QUE inhibited cholesterol metabolism by inhibiting the AGR2/AKT/SREBP2 signaling pathway, enhancing CIS sensitivity to CIS-resistant CAL-27 cells (60). This evidence concerns the gene AKT1 and in situ carcinoma.